Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN EBITDA Margin
EBITDA as a percentage of revenue.
Clene Inc.NASDAQ: CLNN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -46300.0%
EBITDA Margin was -46300.0% in Q1 FY2026, down 46622.2 pp from a year earlier. On a trailing-twelve-month basis it was -21792.5%, down 14931.4 pp year over year. Over 3 fiscal years it narrowed by 5585.1 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -6475.1% for the fiscal year ending Dec 2026, up from -10998.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -46300.0%-35754.5 pp QoQ
- Last fiscal yearDec 2025
- -10998.0%-1146.8 pp YoY
- LTMMar 2026
- -21792.5%-14931.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -10998.0%
- Year-over-year change
- -1146.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -10998.0% | -1146.8pp |
| FY2024 | 2024-12-31 | -9851.2% | -3239.4pp |
| FY2023 | 2023-12-31 | -6611.8% | -1198.9pp |
| FY2022 | 2022-12-31 | -5412.9% | -4259.0pp |
| FY2021 | 2021-12-31 | -1153.9% | — |
EBITDA Margin vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's LTM Mar 2026 EBITDA Margin of -21792.5% is the 7th highest of the 8 companies compared; the peer median is -287.2%.
- Its year-over-year change of -14931.4 pp is the 6th highest of 7, against a peer median of -19.8 pp.
- Over three fiscal years its change of -5585.1 pp compares with a peer median of +3368.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 3772.2% | — | +5140.2 pp | |
| LTM Mar 2026 | -32.2% | -1.2 pp | +32.0 pp | |
| LTM Mar 2026 | -265.8% | +218.0 pp | — | |
WHWKWhitehawk Therapeutics Inc | FY2025 | -287.2% | -38.4 pp | +99.3 pp |
| LTM Mar 2026 | -337.0% | +4411.9 pp | +3368.5 pp | |
| LTM Mar 2026 | -4623.1% | -3172.4 pp | +10652.3 pp | |
| LTM Mar 2026 | -21792.5% | -14931.4 pp | -5585.1 pp | |
| FY2025 | -85279.7% | -85223.0 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CLNN) | -287.2% | -19.8 pp | +3368.5 pp | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 723K | 473K | 654K | 342K | 200K |
| Cost of Revenue | 289K | 26K | 121K | 70K | 43K |
| Gross Profit | 434K | 447K | 533K | 272K | 157K |
| Gross Margin | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| Research & Development | 28.42M | 31.92M | 26.66M | 20.06M | 14.01M |
| Selling, General & Admin | 18.81M | 16.16M | 14.42M | 13.31M | 9.23M |
| Operating Expenses | 50.41M | 48.86M | 41.07M | 33.37M | 23.24M |
| Depreciation & Amortization | 955K | 1.02M | 1.71M | 1.65M | 1.5M |
| EBITDA | (8.34M) | (25.6M) | (43.24M) | (33.69M) | (22M) |
| EBITDA Margin | -1153.9% | -5412.9% | -6611.8% | -9851.2% | -10998.0% |
| Operating Income | (49.98M) | (48.41M) | (40.54M) | (33.09M) | (23.08M) |
| Operating Margin | -6912.6% | -10234.5% | -6198.8% | -9676.3% | -11541.5% |
| Interest Income | 0 | 0 | 1.39M | 865K | 223K |
| Interest Expense | 870K | 3.3M | 4.56M | 4.06M | 2.68M |
| Other Income / Expenses | 39.81M | 18.49M | (8.96M) | (6.31M) | (3.09M) |
| Income Before Tax | (10.17M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Pre-Tax Margin | -1406.4% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| Income Tax Expense | (428K) | 0 | 0 | 0 | 0 |
| Net Income | (9.74M) | (29.92M) | (49.5M) | (39.4M) | (26.17M) |
| Net Margin | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| EPS (Basic) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| EPS (Diluted) | (3.16) | (4.69) | (9.43) | (5.67) | (2.65) |
| Weighted Avg Shares | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
| Weighted Avg Shares (Diluted) | 3.08M | 3.26M | 5.25M | 6.95M | 9.86M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.